Abstract
The purpose of this novel research is to explore the formation of inclusion complexes of a drug, namely, chloroquine diphosphate with cyclic oligosaccharides. The solubility, versatility and bioavailability of the drug are enhanced and some of its side effects are reduced after encapsulation. Various sophisticated approaches have been employed to synthesize and characterize the inclusion phenomenon, which confirm the 1:1 stoichiometry of the complexes. The association constant is found higher in case of β-cyclodextrin which was explicated based on their molecular structure. The work explores the enhancement of overall bioavailability of this essential biologically active molecule.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Cyclodextrins (CD) are the most fascinating host molecules in supramolecular chemistry [1]. They have the capacity to construct stable encapsulated complexes (inclusion complex, IC) with various guest molecules on account of their exceptional truncated cone structure [2,3,4,5,6,7]. Stabilisation by hydrophobic interaction between the cavity of the cyclodextrin and hydrophobic part of the guest molecule is responsible for the formation of this type of steady host–guest encapsulated complexes. The weak intermolecular forces acting between the host and guest molecules are mainly van der Waals force, dipolar interaction, electrostatic and hydrogen bonding attractions [8]. They are broadly used in the pharmaceutical production as drug carrier to modify the bioavailability of biologically active molecules [9]. They are non-poisonous and can be taken safely by humans. Cyclodextrin based inclusion is the best method to develop inclusion complexes to improve the physicochemical properties of the drug molecule [10]. CDs are macro cyclic water soluble oligosaccharides composed of six (α-CD), seven (β-CD) and eight (γ-CD) glucopyranose units linked through α-(1–4) bond [11]. Primary hydroxyl groups are situated at narrow end and secondary hydroxyl groups are placed around the wider end (Scheme 1) [12]. This type of unique structure permits them to enclose comprehensive guest molecules.
The drug chloroquine diphosphate (CDP) is a medicine that is primarily used to prevent and treat malaria (Scheme 2). Certain types of complicated cases of malaria typically require additional medication. CDP is occasionally used for amebiasis, rheumatoid arthritis and lupus erythematosus. [13, 14] It is a component of drug class 4-aminoquinoline. It appears to be safe during pregnancy time. It works in opposition to the asexual form of malaria inside red blood cell. This drug has some ordinary side effects including muscle problems, loss of hunger, diarrhea and skin complaint [15]. Controlled release of this drug using CD as the encapsulating agent can minimize these side effects and the drug molecule should be able to penetrate the lipophilic membrane to facilitate its biological activity. By forming inclusion complex CD can transport the drug to the physiological spot without losing any of its bioactivity [9].
In this article we endeavor to explore the formation and nature of IC of CDP with two cyclic oligosaccharides in aqueous environment with the help of spectroscopic and physicochemical studies keeping in mind that the drug molecule must retain its biological activity.
Experimental section
Source and purity of samples
Chloroquinediphosphate, α-CD and β-CD of puriss grade were purchased from Sigma-Aldrich, Germany and used in the experiment as it received. The mass fraction purity of CDP, α-CD and β-CD were ≥ 0.98, ≥ 0.99 and ≥ 0.98 respectively.
Apparatus and procedure
Triple distilled & degassed water was utilized for checking the solubility of the drug CDP, α-CD and β-CD. The drug and both the CD molecules are completely soluble in water. The solutions were set up by mass at 298.15 K. Solutions were made with proper care to avoid weight loss by evaporation.
1H NMR was done at 300 MHz in D2O solution using Bruker Avance machine at 298 K. Signals are shown as δ in ppm using solvent signals (HDO: δ 4.79 ppm) as internal standard.
Surface tension experiment was done by tensiometer (K9, KRUSS; Germany) by platinum ring detachment at 298.15 K. During experiment the temperature of the system was kept constant by thermostat water circulating through double wall glass vessel enclosing the solution.
The conductances of the solutions were determined by MT Seven Multi conductivity meter. The uncertainty of the result was approximately ± 1.0 µSm−1. The experiments were done in a thermostat water bath keeping the temperature fixed at 298.15 K.
Ultra-violet visible spectra were recorded by spectrophotometer (JASCO V-530), with an uncertainty ± 2 nm. A digital thermostat was used to keep the temperature constant.
Fourier transform IR spectra were taken on a spectrometer (Perkin Elmer) applying the KBr disk procedure. Samples were formulated as KBr disks with complex (1 mg) and KBr (100 mg). The scanning range was 4000−400 cm−1 at normal temperature.
HRMS were performed with Q-TOF instrument (high resolution) by positive mode electro-spray ionization.
ICs (α-CD + CDP and β-CD + CDP) were also prepared in the solid state taking 1:1 mol ratio of the drug CDP and each CD. For this purpose 1.0 mmol CD was dissolved in 20 mL water and 1.0 mmol drug CDP was dissolved in 20 mL water. These two solutions are allowed to stir separately in a magnetic stirrer for 3 h. The aqueous solution of the drug was added dropwise into the aqueous solution of the cyclodextrin. Then the mixture is constantly stirred for 4 days at 40–45 °C. The solution was filtered at that temperature, then cooled to 5 °C and kept for 24 h. The resulting suspension was filtered and the white polycrystalline powder was found, it was dried in air.
Result and discussion
1H NMR spectra analysis
The formation of IC and stoichiometry is verified by 1H NMR study. When the drug molecule is encapsulated into the hydrophobic cavity of CD molecule it consequences the shift of protons of the CDP and CD molecules [16, 17]. The aromatic ring of CDP molecule produces diamagnetic shielding of protons present in it according to the interaction with the CD protons after encapsulation. The location of various protons in the CD molecules are illustrated in Scheme 3. The protons H3 and H5 are located within the cone of CD close to the wider rim and narrower rim respectively. The remaining H1, H2 and H4 protons have their positions at the outer surface of the CD molecule [18,19,20]. The chemical shift (δ) values of the drug CDP, α-CD, β-CD and ICs are mentioned in table S1. The signals of the protons of the host and aromatic ring of the drug shifted towards upfield in the resulting inclusion complex of the drug and CD (Figs. 1, 2). Chemical shift indicates that the aromatic moiety of the drug interact with the H3 than H5 protons signifying that the drug molecule enter into the hydrophobic cavity from wider rim. The change in δ value of CDP and CD is mainly because of change of environment after inclusion complex formation. The upfield shift is basically due to formation of hydrogen bond of the guest with rim hydroxyl groups of CD. The shielding of H3 and H5 protons are due to ring current effect as the aromatic part of the ring was positioned perpendicular to the to the cyclodextrin molecule cavity [2]. These results show the formation of inclusion complex.
Surface tension study
Surface tension study nicely explains the formation of IC [21, 22]. CDs being hydrophobic in nature do not express considerable change of surface tension (γ) of aqueous solution [23]. The drug molecule CDP exist as charged structure and behave like surface active molecule. Therefore when CDP forms IC with the host molecule notable modification in surface tension is detected. The γ value of the aqueous solution of this drug is less than that of water. In this article the γ value of various solutions of CDP with gradual addition of α and β-CD were determined at 298.15 K (Tables S4, S5). The γ regularly increases for both the CDs, perhaps owing to the inclusion of the surfactant like drug molecules from solution to the hydrophobic cavity of the CDs (Scheme 4). There is a solo noticeable break in both the plots (Fig. 3) which propose the formation of IC [24, 25]. The concentration ratios of the CDs and CDP at the break point (Table 1) are roughly 1:1 which surely indicate the stoichiometric ratio of the IC to be 1:1. If more than one break point would be detected in the surface tension plot it would indicate other stoichiometry of the IC.
Conductivity study
Conductivity (κ) provides important information concerning the stoichiometry of the IC [26, 27]. The aqueous solution of the drug CDP is conductive in nature as it can exist as a charged structure. For this purpose the conductivity of a sequence of solutions of this drug with gradual addition of α and β-CD were determined at 298.15 K. When dropwise CD solution is added to the drug solution the conductivity value regularly decreases and there is an appearance of a sharp break point after that the conductivity value do not show any change (Tables S6, S7). α and β-CD show same type of tendency in their conductivity values (Fig. 4). The manifestation of sharp break points imply the formation of IC [3, 28]. The decreasing κ value is mainly due to the insertion of the guest drug molecule in the conical cavity of CD. The values of κ and subsequent concentration of the CD molecules are mentioned in Table 1 which proposes that the ratio of concentration of CDP and the CD at the break point is around 1:1. This confirms the stoichiometry of the IC to be 1:1.
The break point is the point at which the conductivity value corresponds to the maximum inclusion of the drug molecules in CD molecule cavity [18]. There exists an active equilibrium between the free and encapsulated drug molecules.
Job plots confirm the stoichiometric ratio
Job’s method can be utilized to recognize the stoichiometry of the ICs formed [29, 30]. Job plots are constructed by the continuous variation method by UV–Visible spectroscopy. For this purpose a series of solutions for the drug CDP and both the CDs were prepared with the variation of the mole fraction of the drug molecule (Tables S2, S3). ∆A × ∆R was plotted against R to obtain these plots where ∆A is the difference in the absorbance of the drug without and with the presence of host CDs and R = [CDP]/([CDP] + [CD]) [21, 31]. Absorbance values were recorded at the respective λmax for each of the solutions at 298.15 K. The stoichiometry of the inclusion complex was found from the R values at maximum deviation, that is the ratio of host and guest at R = 0.5 is for 1:1 complex; R = 0.33 for 1:2 complex; R = 0.66 for 2:1 complex [8]. From Fig. 5, it has been found that the maxima is at R = 0.5 for each plot which confirms the 1:1 stoichiometry of the ICs.
Association constant and thermodynamic parameters
Association constants were determined for both the CDP-CD ICs from UV–Visible spectra [32]. When the drug molecule is encapsulated in the CD cavity there is a change from polar aqueous environment to the apolar hydrophobic cavity. As a result the change in molar absorptivity (∆ε) of the drug molecule changes after inclusion. The difference in absorbance intensity (∆A) of the drug is observed as a function of concentration of both the CD molecules to find out the Ka value (Tables 2, S2 and S3). Double reciprocal plots were generated on the basis of Benesi–Hildebrand method for 1:1 host–guest ICs [8, 33] (Figs. S1, S2, Eq. 1)
The aforementioned equation is a linear one and the Ka was calculated dividing intercept by slope from double-reciprocal plots for both the ICs [34].
The thermodynamic parameters can also be evaluated using the Ka values found at various temperatures on the basis of above method using van’t Hoff equation mentioned below [35].
Linear relationship exists between lnKa and 1/T. The slope of the plot of equilibrium constant at various temperatures gives a negative value for ΔH°, thus indicating that the process is exothermic [31]. The thermodynamic parameters are listed in Table 2. The negative values of ΔG° for both systems indicate that the formation of inclusion complexes is spontaneous. The decrease in ΔS° value implies that the process is entropy controlled but not entropy driven. The negative value of ΔS°, unfavorable to the inclusion process, is overcome by the negative value of ΔH°, leading to an overall thermodynamically favorable process.
The entropic contribution for β-CD is less unfavorable compared to α-CD as found from the spectroscopic studies. This may be attributed to the fact that both α and β-CD comprise of few water molecules inside the cavity. While the hydrophobic guest enters into the cavity of CD, these water molecules are released into the bulk increasing the overall entropy of the system. Now, as found from the other studies that β-CD has higher tendency for the formation of inclusion complex, it is typical that the drop of entropy would be much less in case of β-CD as respect to α-CD.
FT-IR spectra analysis
FT-IR spectral study helps to determine the interaction between the host and guest in the IC [36, 37]. The drug CDP and the CDs form solid inclusion complexes by other than covalent interactions such as hydrophobic interactions, van der Waals interaction and hydrogen bonding. After encapsulation of the drug molecule by the CDs, the resulting absorption bands from the encapsulated part of the guest have been shifted in their position [38, 39]. The FT-IR spectrum of pure CDP, α-CD, β-CD and the two ICs are shown in the Figs. 6 and 7. The different frequencies of the above mentioned compounds are reported in table S10. The spectrum of CDP is characterised by peaks of –N–H, –C=N, –C–N, –C–Cl, aromatic –C=C, –C–H of –CH2 and –CH3 etc. The broad –O–H stretching frequency for α-CD and β-CD was observed at 3412.11 cm−1 and 3349.85 cm−1 respectively. In the ICs the –O–H frequency shifted to lower region i.e., 3384.08 and 3329.76 cm−1 for α-CD and β-CD respectively. This shift occurs probably due to participation of the –O–H groups of both the CDs in hydrogen bonding with the guest drug molecule. The peaks of –C=N, –C–N, aromatic –C=C of the drug CDP are shifted in the spectra of the ICs. The changes in the FT-IR spectra of ICs are due to the restriction of the vibration of free CDP molecules as the quinoline part of the drug with Cl groups is encapsulated in the hollow space of CD molecules [40, 41]. No additional peaks are found in the spectra of the ICs. This fact again confirms that only non covalent interaction exists between the host and guest, only Vanderwaal’s interaction are present.
HRMS study
ESI–MS study is a extensively acknowledged practice to describe host–guest IC [42, 43]. The result of ESI–MS study can simply be matched up with other experiments, for instance Job Plot titration obtained from UV–Visible spectra. The solid ICs synthesized by the method mentioned in the experimental section are used for MS study. Figure 8a, b show the mass spectra of the two CDP-CD ICs. The strong peaks at m/z 1293.54 and 1454.61 refers to the proton adduct of CDP + α-CD IC and CDP + β-CD IC. Since no additional intense peak was detected at higher values the ESI–MS experiment verifies the 1:1 stoichiometry of the ICs [44, 45].
Conclusion
It can be concluded from the present study that chloroquine diphosphate form ICs with α-CD and β-CD in aqueous solution and in solid phase, thus enhances the bioavailability of the drug. These two inclusion complexes have found applications for controlled release of this drug. The inclusion phenomenon is explained by 1H-NMR study whereas surface tension, conductivity and Job plot variation suggest the 1:1 stoichiometry of the ICs. FTIR and HRMS also support the formation of IC. The binding constants and thermodynamic data are determined by UV–Visible spectroscopy which is come across to be higher for β-CD. In general the inclusion process is thermodynamically approving. These two ICs have potential application in the pharmaceutical industries and biomedical fields.
References
Li, H., Chen, D., Sun, Y., Zheng, Y., Tan, L., Weiss, P.: Viologen-mediated assembly of and sensing with carboxylatopillar[5]arene-modified gold nanoparticles. J. Am. Chem. Soc. 135, 1570–1576 (2013)
Negi, J.S., Singh, S.: Spectroscopic investigation on the inclusion complex formation between amisulpride and γ-cyclodextrin. Carbohydr. Polym. 92, 1835–1843 (2013)
Roy, M.N., Roy, A., Saha, S.: Probing inclusion complexes of cyclodextrins with amino acids by physicochemical approach. Carbohydr. Polym. 151, 458–466 (2016)
Saha, S., Roy, A., Roy, K., Roy, M.N.: Study to explore the mechanism to form inclusion complexes of β-cyclodextrin with vitamin molecules. Sci. Rep. 6, 35764 (2016)
Roy, A., Saha, S., Dutta, B., Roy, M.N.: Insertion behavior of imidazolium and pyrrolidinium based ionic liquids into α and β cyclodextrins: mechanism and factors leading to host–guest inclusion complexes. RSC Adv. 6, 100016–100027 (2016)
Roy, M.N., Roy, K., Das, K., Barman, B.K.: Self assembly inclusion of green solvents with oligosachharides. J. Mol. Liq. 216, 432–436 (2016)
Dutta, B., Barman, S., Roy, M.N.: Self assembly inclusion of ionic liquid into holo cylinder oligosaccharides. J. Mol. Liq. 214, 264–269 (2016)
Wei, B.: β-Cyclodextrin associated polymeric systems: rheology, flow behavior in porous media and enhanced heavy oil recovery performance. Carbohydr. Polym. 134, 398–405 (2015)
Pinho, E., Grootveld, M., Soares, G., Henriques, M.: Cyclodextrins as encapsulation agents for plant bioactive compounds. Carbohydr. Polym. 101, 121–135 (2014)
Aytac, Z., Yildiz, Z.I., Kayaci-Senirmak, F., Keskin, N.O.S., Kusku, S.I., Durgun, T.E., Uyar, T.: Fast-dissolving, prolonged release, and antibacterial cyclodextrin/limonene-inclusion complex nanofibrous webs via polymer-free electrospinning. J. Agric. Food Chem. 64, 7325–7334 (2016)
Yao, Y., Liu, X., Liu, T., Zhou, J., Zhu, J., Sun, G., He, D.: Preparation of inclusion complex of perfluorocarbon compound with β-cyclodextrin for ultrasound contrast agent. RSC Adv. 5, 6305 (2015)
Dinar, K., Sahra, K., Seridi, A., Kadri, M.: Inclusion complexes of N-sulfamoyloxazolidinones with β-cyclodextrin: a molecular modeling approach. Chem. Phys. Lett. 595–596, 113–120 (2014)
"Aralen Phosphate". The American Society of Health-System Pharmacists. Accessed 2 Dec 2015
Health information for international travel 2001. U.S. Department of Health and Human Services, Public Health Service, Atlanta (2001)
DailyMed—CHLOROQUINE- chloroquine phosphate tablet CHLOROQUINE- chloroquine phosphate tablet, coated. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b585ad5-ae86-4403-b83f-8d8363d43da5. Accessed 3 Nov 2015
Bani-Yaseen, A.D., Mo’ala, A.: Spectral, thermal, and molecular modeling studies on the encapsulation of selected sulfonamide drugs in β-cyclodextrin nano-cavity. Spectrochim. Acta A 131, 424–431 (2014)
Wang, L., Li, S., Tang, P., Yan, J., Xu, K., Li, H.: Characterization and evaluation of synthetic riluzole with β-cyclodextrin and 2,6-di-O-methyl-β-cyclodextrin inclusion complexes. Carbohydr. Polym. 129, 9–16 (2015)
Saha, S., Ray, T., Basak, S., Roy, M.N.: NMR, surface tension and conductivity studies to determine inclusion mechanism: thermodynamics of host–guest inclusion complexes of natural amino acids in aqueous cyclodextrins. New J. Chem. 40, 651–661 (2016)
Caso, J.V., Russo, L., Palmieri, M., Malgieri, G., Galdiero, S., Falanga, A., Isernia, C., Iacovino, R.: Investigating the inclusion properties of aromatic amino acids complexing beta-cyclodextrins in model peptides. Amino Acids 47, 2215–2227 (2015)
Wang, T., Wang, M.D., Ding, C., Fu, J.: Mono-benzimidazole functionalized β-cyclodextrins as supramolecular nanovalves for pH-triggered release of p-coumaric acid. Chem. Commun. 50, 12469–12472 (2014)
Roy, M.N., Saha, S., Barman, S., Ekka, D.: Host–guest inclusion complexes of RNA nucleosides insight into aqueous cyclodextrins explored by physicochemical and spectroscopic contrivances. RSC Adv. 6, 8881–8891 (2016)
Gao, Y., Zhao, X., Dong, B., Zheng, L., Li, N., Zhang, S.: Inclusion complexes of β-cyclodextrin with ionic liquid surfactants. J. Phys. Chem. B 110, 8576–8581 (2006)
Roy, M.N., Ekka, D., Saha, S., Roy, M.C.: Host–guest inclusion complexes of α and β-cylodextrins with α-amino acids. RSC Adv. 4, 42383–42390 (2014)
Pineiro, A., Banquy, X., Casas, S.P., Tovar, E., Garcia, A., Villa, A., Amigo, A., Mark, A.E., Costas, M.: On the characterization of host−guest complexes: surface tension, calorimetry, and molecular dynamics of cyclodextrins with a non-ionic surfactant. J. Phys. Chem. B 111, 4383–4392 (2007)
Gao, Y., Li, Z., Du, J., Han, B., Li, J., Hou, W., Shen, D., Zheng, L., Zhang, G.: Preparation and characterization of inclusion complexes of β-cyclodextrin with ionic liquid. Chem. Eur. J. 11, 5875–5880 (2005)
Apelblat, A., Manzurola, E., Orekhova, Z.: Electrical conductance studies in aqueous solutions with glutamic ions. J. Solut. Chem. 36, 891–900 (2007)
Qian, T., Yu, C., Wu, S., Shen, J.: Gold nanoparticles coated polystyrene/reduced graphite oxide microspheres with improved dispersibility and electrical conductivity for dopamine detection. Colloids Surf. B. 112, 310–314 (2013)
Roy, A., Saha, S., Roy, M.N.: Study to explore host–guest inclusion complexes of cyclodextrins with biologically active molecules in aqueous environment. Fluid Phase Equilib. 425, 252–258 (2016)
Job, P.: Formation and stability of inorganic complexes in solution. Ann. Chim. 9, 113–203 (1928)
Renny, J.S., Tomasevich, L., Tallmadge, E.H., Collum, D.B.: Method of continuous variations: applications of job plots to the study of molecular associations in organometallic chemistry. Angew. Chem. Int. Ed. 52, 11998–12013 (2013)
Roy, M.N., Saha, S., Kundu, M., Saha, B.C., Barman, S.: Exploration of inclusion complexes of neurotransmitters with β-cyclodextrin by physicochemical techniques. Chem. Phys. Lett. 655–656, 43–50 (2016)
Cramer, F., Saenger, W., Spatz, H.: Inclusion compounds. The formation of inclusion compounds of α-cyclodextrin in aqueous solutions. Thermodynamics and kinetics. J. Am. Chem. Soc. 89, 14–20 (1967)
Benesi, H.A., Hildebrand, J.H.: A spectrophotometric investigation of the interaction of iodine with aromatic hydrocarbons. J. Chem. Soc. 71, 2703–2707 (1949)
Dotsikas, Y., Kontopanou, E., Allagiannis, C., Loukas, Y.L.: Interaction of 6-p-toluidinylnaphthalene-2-sulphonate with beta-cyclodextrin. J. Pharm. Biomed. Anal. 23, 997–1003 (2000)
He, Y., Shen, X.: Interaction between βcyclodextrin and ionic liquids in aqueous solutions investigated by a competitive method using a substituted 3Hindole probe. J. Photochem. Photobiol. A 197, 253–259 (2008)
Xiao, C., Li, K., Huanga, R., Hea, G., Zhang, J., Zhu, L., Yang, Q., Jiang, K., Jin, Y., Lin, J.: Investigation of inclusion complex of epothilone A with cyclodextrins. Carbohydr. Polym. 102, 297–305 (2014)
Stalin, T., Srinivasan, K., Sivakumar, K., Radhakrishnan, S.: Preparation and characterizations of solid/aqueous phases inclusion complex of 2,4-dinitroaniline with β-cyclodextrin. Carbohydr. Polym. 107, 72–84 (2014)
Sivakumar, K., Ragi, T.R., Prema, D., Stalin, T.: Experimental and theoretical investigation on the structural characterization and orientation preferences of 2-hydroxy-1-naphthoic acid/β-cyclodextrin host–guest inclusion complex. J. Mol. Liq. 218, 538–548 (2016)
Misiuk, W., Jozefowicz, M.: Study on a host–guest interaction of hydroxypropyl-β-cyclodextrin with ofloxacin. J. Mol. Liq. 202, 101–106 (2015)
Rajendiran, N., Siva, S.: Inclusion complex of sulfadimethoxine with cyclodextrins: preparation and characterization. Carbohydr. Polym. 101, 828–836 (2014)
Rajendiran, N., Venkatesh, G., Mohandass, T.: Fabrication of 2D nanosheet through self assembly behavior of sulfamethoxypyridazine inclusion complexes with α and β cyclodextrins. Spectrochim. Acta A 123, 158–166 (2014)
Zhang, J., Jiang, K., An, K., Ren, S., Xie, X., Jin, Y., Lin, J.: Novel water-soluble fisetin/cyclodextrins inclusion complexes: preparation, characterization, molecular docking and bioavailability. Carbohydr. Res. 418, 20–28 (2015)
Okada, Y., Ueyama, K., Nishikawa, J., Semma, M., Ichikawa, A.: A effect of 6-O-α-maltosyl-β-cyclodextrin and its cholesterol inclusion complex on cellular cholesterol levels and ABCA1 and ABCG1 expression in mouse mastocytoma P-815 cells. Carbohydr. Res. 357, 68–74 (2012)
Ceborska, M., Zimnicka, M., Wszelaka-Rylik, M., Troc, A.: Characterization of folic acid/native cyclodextrins host guest complexes in solution. J. Mol. Struct. 1109, 114–118 (2016)
Szabó, Z., Tóth, G., Völgyi, G., Komjáti, B., Hancu, G., Szente, L., Sohajda, T., Béni, S., Muntean, D.L., Noszál, B.: Chiral separation of asenapine enantiomers by capillary electrophoresis and characterization of cyclodextrin complexes by NMR spectroscopy, mass spectrometry and molecular modeling. J. Pharm. Biomed. Anal. 117, 398–404 (2016)
Acknowledgements
Authors convey their thanks to the SAP, Department of Chemistry, UNB under UGC, New Delhi for financial support and necessary instruments to complete the research work. Prof. Roy was also very thankful to UGC, New Delhi, Government of India, for being honored grant under basic scientific research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors announce they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Roy, A., Saha, S., Roy, D. et al. Formation & specification of host–guest inclusion complexes of an anti-malarial drug inside into cyclic oligosaccharides for enhancing bioavailability. J Incl Phenom Macrocycl Chem 97, 65–76 (2020). https://doi.org/10.1007/s10847-020-00984-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10847-020-00984-1